Kyiv is an important industrial, scientific, educational, and cultural center in Eastern Europe. It is home to many high-tech industries, higher education institutions, and historical landmarks. The city has an extensive system of public transport and infrastructure, including the Kyiv Metro.

Ukraine agrees to 30-day ceasefire if Russia abides by it, Kyiv says. Kyiv is ready to accept Washington's proposal to immediately implement a temporary, 30-day ceasefire which can be extended by mutual agreement, the Presidential Office announced on March 11 after the talks with the U.S. in Saudi Arabia.

Higher education increases our ability to approach situations with reason, empathy and creativity. It is a powerful force against prejudice and fear. We have an opportunity to emerge from this moment as a more just and equitable society.

Kyiv Post debunks The Telegraph’s report on Ukraine’s battlefield tactics, exposing inaccuracies, misleading claims, and questionable sources saying Ukraine ignored NATO training and …

KYB has you covered with shocks that restore performance and performance upgrade shock absorbers and struts for trucks. This is why we do it! KYB TV is a series of short videos developed to help you understand what shocks and struts do, how they affect performance, and why KYB is the correct choice. View all videos.

KYV-101 is a novel, fully human CD19 CAR T-cell therapy for use in B cell-driven autoimmune diseases such as lupus nephritis, a serious complication of lupus.

Find the latest Kyverna Therapeutics, Inc. (KYTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

2024年1月5日 · The U.S. Food and Drug Administration (FDA) has cleared a Phase 2 clinical trial to test Kyverna Therapeutics ‘ cell-based therapy candidate KYV-101 in people with treatment-resistant...

Kyverna is the exclusive worldwide licensee of a next-generation CAR T construct targeting CD19 for use in autologous (KYV-101 and KYV-102) and allogeneic (KYV-201) cell therapies for B-cell driven autoimmune diseases.

Our mission is to liberate autoimmune patients through the curative potential of cell therapy. Kyverna is pioneering a durable disease-clearing approach aiming for deep B cell depletion, an immune system reset, and long-term remission in autoimmune diseases.